keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis a b c d e f

keyword
https://www.readbyqxmd.com/read/29433087/chromium-accumulation-and-biomarker-responses-in-the-neotropical-fish-prochilodus-lineatus-caged-in-a-river-under-the-influence-of-tannery-activities
#1
Bruna Lunardelli, Millena T Cabral, Carlos E D Vieira, Luciana F Oliveira, Wagner E Risso, Paulo C Meletti, Claudia B R Martinez
In order to assess the effects of tannery effluents (TE) in organism health, juveniles of Prochilodus lineatus were submitted to in situ tests at four different river locations: site A - upstream of the tannery; site B - next to the tannery; and sites C and D - downstream of the tannery. After 96 h exposure in the river, samples of fish tissue, river water and sediment were collected in order to quantify chromium (Cr) concentrations. Tissue samples were used to assess the activity of ethoxyresorufin-O-deethylase (EROD) and glutathione S-transferase (GST), the content of glutathione (GSH) and metallothionein (MT) and the occurrence of lipid peroxidation (LPO) and DNA damage...
February 9, 2018: Ecotoxicology and Environmental Safety
https://www.readbyqxmd.com/read/29408986/nivolumab-versus-docetaxel-in-previously-treated-advanced-non-small-cell-lung-cancer-checkmate-017-and-checkmate-057-3-year-update-and-outcomes-in-patients-with-liver-metastases
#2
E E Vokes, N Ready, E Felip, L Horn, M A Burgio, S J Antonia, O Arén Frontera, S Gettinger, E Holgado, D Spigel, D Waterhouse, M Domine, M Garassino, L Q M Chow, G Blumenschein, F Barlesi, B Coudert, J Gainor, O Arrieta, J Brahmer, C Butts, M Steins, W J Geese, A Li, D Healey, L Crinò
Background: Long-term data with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and non-squamous (CheckMate 057) NSCLC. We report results from ≥3 years' follow-up, including subgroup analyses of patients with liver metastases, who historically have poorer prognosis among patients with NSCLC...
February 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29327780/systematic-review-with-meta-analysis-effectiveness-and-tolerability-of-interferon-free-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-genotype-1-in-routine-clinical-practice-in-asia
#3
REVIEW
F Ji, B Wei, Y H Yeo, E Ogawa, B Zou, C D Stave, Z Li, S Dang, N Furusyo, R C Cheung, M H Nguyen
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017...
January 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29322599/non-invasive-evaluation-of-portal-hypertension-using-shear-wave-elastography-analysis-of-two-algorithms-combining-liver-and-spleen-stiffness-in-191-patients-with-cirrhosis
#4
L Elkrief, M Ronot, F Andrade, M Dioguardi Burgio, T Issoufaly, M Zappa, O Roux, J Bissonnette, A Payancé, D Lebrec, C Francoz, O Soubrane, D Valla, F Durand, V Vilgrain, L Castera, P-E Rautou
BACKGROUND: Two algorithms based on sequential measurements of liver and spleen stiffness using two-dimensional shearwave elastography (2D-SWE) have been recently proposed to estimate clinically significant portal hypertension (hepatic venous pressure gradient [HVPG] ≥10 mm Hg) in patients with cirrhosis, with excellent diagnostic accuracy. AIM: To validate externally these algorithms in a large cohort of patients with cirrhosis. METHODS: One hundred and ninety-one patients with stable cirrhosis (Child-Pugh class A 39%, B 29% and C 31%) who underwent liver and spleen stiffness measurements using 2D-SWE at the time of HVPG measurement were included...
January 11, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29315722/very-slow-decline-of-hepatitis-b-virus-surface-antigen-and-core-related-antigen-in-chronic-hepatitis-b-patients-successfully-treated-with-nucleos-t-ide-analogues
#5
E K Alidjinou, C Michel, V Canva, F Ajana, D Hober, L Bocket
We investigated the decline of hepatitis B virus surface antigen (HBsAg) and core related antigen (HBcrAg) in chronic hepatitis B patients sussessfully treated with nucleos(t)ide analogues. In patients with plasma viral suppression, the baseline median levels of HBsAg and HBcrAg were 3.1 log IU/mL and 3.0 log U/mL, respectively. The levels in naïve patients were 4.2 log IU/mL and 3.6 log U/mL for HBsAg and HBcrAg respectively. No significant decline was observed in patients with viral suppression within a year period...
January 9, 2018: Journal of Medical Virology
https://www.readbyqxmd.com/read/29274193/efficacy-and-safety-of-6-or-8-weeks-of-simeprevir-daclatasvir-sofosbuvir-for-hcv-genotype-1-infection
#6
M S Sulkowski, J J Feld, E Lawitz, F Felizarta, A M Corregidor, O Khalid, R Ghalib, W B Smith, V Van Eygen, D Luo, L Vijgen, M Gamil, T N Kakuda, S Ouwerkerk-Mahadevan, P Van Remoortere, M Beumont
The phase 2, open-label ACCORDION (ClinicalTrials. gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1 infection and either early-stage fibrosis or compensated cirrhosis. Patients were assigned to treatment groups according to their fibrosis stage. Early-stage fibrosis: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once daily for 6 weeks; compensated cirrhosis: same regimen for 8 weeks...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29248218/diagnostic-performance-of-cytology-for-assessment-of-hepatic-lipid-content-in-dairy-cattle
#7
M M Fry, B Yao, C Ríos, C Wong, S Mann, J A A McArt, D V Nydam, F A Leal Yepes, L Viesselmann, A Geick, K Goldin, A Jordan, E Behling-Kelly
The objective of our study was to characterize the diagnostic performance of cytology for assessing hepatic lipid content (HLC) in dairy cows by comparing microscopic evaluation of lipid vacuolation in touch imprint slide preparations of liver biopsies with quantitative measurement of triglyceride concentration ([TG]; mg/mg of wet weight) in paired biopsy samples. Our study also sought to compare the diagnostic performance of liver cytology, plasma nonesterified fatty acid concentration ([NEFA]), and plasma β-hydroxybutyrate concentration ([BHB]) derived from a measurement performed on whole blood, for assessing HLC...
December 13, 2017: Journal of Dairy Science
https://www.readbyqxmd.com/read/29192364/liver-metastases-from-prostate-cancer-at-11c-choline-pet-ct-a-multicenter-retrospective-analysis
#8
Pietro Ghedini, I Bossert, L Zanoni, F Ceci, T Graziani, P Castellucci, V Ambrosini, F Massari, E Nobili, B Melotti, A Musto, S Zoboli, L Antunovic, M Kirienko, A Chiti, C Mosconi, A Ardizzoni, R Golfieri, S Fanti, C Nanni
AIM: During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but significant occurrence of hypodense hepatic lesions with a different tracer uptake. Thus, we decided to evaluate the possible correlation between rPCa and these lesions as possible hepatic metastases. MATERIALS AND METHODS: We retrospectively enrolled 542 patients diagnosed with rPCa in biochemical relapse after a radical treatment (surgery and/or radiotherapy)...
November 30, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29145578/the-changing-paradigm-of-management-of-liver-abscesses-in-chronic-granulomatous-disease
#9
David M Straughan, Kaitlin C McLoughlin, John E Mullinax, Beatriz E Marciano, Alexandra F Freeman, Victoria L Anderson, Gulbu Uzel, Sa D C Azoury, Rebecca Sorber, Humair S Quadri, Harry L Malech, Suk See DeRavin, Natasha Kamal, Christopher Koh, Christa S Zerbe, Douglas B Kuhns, John I Gallin, Theo Heller, Steven M Holland, Udo Rudloff
Background: Chronic granulomatous disease (CGD) is a rare genetic disorder causing recurrent infections. Over one quarter of patients develop hepatic abscesses and liver dysfunction. Recent reports suggest disease-modifying treatment with corticosteroids is effective for these abscesses. Comparison of corticosteroid therapy to traditional invasive treatments has not been performed. Methods: Records of 268 patients with CGD treated at the National Institutes of Health (NIH) from 1980 to 2014 were reviewed...
November 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29105286/strategies-to-manage-hepatitis-c-virus-infection-disease-burden-volume-4
#10
D S Chen, W Hamoudi, B Mustapha, J Layden, A Nersesov, T Reic, V Garcia, C Rios, L Mateva, O Njoya, S A Al-Busafi, M K Abdelmageed, M Abdulla, D Adda, O Akin, A Al Baqali, N Al Dweik, K Al Ejji, I Al Ghazzawi, S Al Kaabi, K Al Naamani, J Al Qamish, M Al Sadadi, J Al Salman, M AlBadri, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, A Bane, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, I Cardenas, H L Y Chan, C J Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, M Derbala, A A Elbardiny, C Estes, E Farag, J Fung, I Gamkrelidze, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, S M Himatt, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, K S Kaliaskarova, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A Maaroufi, A O Malu, R Mitova, R Mohamed, M Morović, K Murphy, H Nde, E Ngige, R Njouom, D Nonković, S Obekpa, S Oguche, E E Okolo, O Omede, C Omuemu, P Ondoa, O Opare-Sem, S Owusu-Ofori, R O Phillips, Y N Prokopenko, H Razavi, D Razavi-Shearer, K Razavi-Shearer, B Redae, T Rinke de Wit, S Robbins, L R Roberts, S J Sanad, M Sharma, M Simonova, T H Su, K Sultan, S S Tan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, A Vince, H U Wani, V W S Wong, A Workneh, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, J D Schmelzer
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets-"WHO Targets" (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29105285/historical-epidemiology-of-hepatitis-c-virus-in-select-countries-volume-4
#11
A Maaroufi, A Vince, S M Himatt, R Mohamed, J Fung, O Opare-Sem, A Workneh, R Njouom, I Al Ghazzawi, M Abdulla, K S Kaliaskarova, S Owusu-Ofori, M K Abdelmageed, D Adda, O Akin, A Al Baqali, N Al Dweik, K Al Ejji, S Al Kaabi, K Al Naamani, J Al Qamish, M Al Sadadi, J Al Salman, M AlBadri, S A Al-Busafi, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, A Bane, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, I Cardenas, H L Y Chan, C J Chen, D S Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, M Derbala, A A Elbardiny, C Estes, E Farag, I Gamkrelidze, V Garcia, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, W Hamoudi, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, J Layden, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A O Malu, L Mateva, R Mitova, M Morović, K Murphy, B Mustapha, H Nde, A Nersesov, E Ngige, O Njoya, D Nonković, S Obekpa, S Oguche, E E Okolo, O Omede, C Omuemu, P Ondoa, R O Phillips, Y N Prokopenko, H Razavi, D Razavi-Shearer, B Redae, T Reic, T Rinke de Wit, C Rios, S Robbins, L R Roberts, S J Sanad, J D Schmelzer, M Sharma, M Simonova, T H Su, K Sultan, S S Tan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, H U Wani, V W S Wong, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, K Razavi-Shearer
Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country-specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29105283/the-present-and-future-disease-burden-of-hepatitis-c-virus-infections-with-today-s-treatment-paradigm-volume-4
#12
H L Y Chan, C J Chen, O Omede, J Al Qamish, K Al Naamani, A Bane, S S Tan, M Simonova, I Cardenas, M Derbala, O Akin, R O Phillips, M K Abdelmageed, M Abdulla, D Adda, A Al Baqali, N Al Dweik, K Al Ejji, I Al Ghazzawi, S Al Kaabi, M Al Sadadi, J Al Salman, M AlBadri, S A Al-Busafi, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, D S Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, A A Elbardiny, C Estes, E Farag, J Fung, I Gamkrelidze, V Garcia, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, W Hamoudi, S M Himatt, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, K S Kaliaskarova, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, J Layden, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A Maaroufi, A O Malu, L Mateva, R Mitova, R Mohamed, M Morović, K Murphy, B Mustapha, A Nersesov, E Ngige, R Njouom, O Njoya, D Nonković, S Obekpa, S Oguche, E E Okolo, C Omuemu, P Ondoa, O Opare-Sem, S Owusu-Ofori, Y N Prokopenko, H Razavi, D Razavi-Shearer, K Razavi-Shearer, B Redae, T Reic, T Rinke de Wit, C Rios, S Robbins, L R Roberts, S J Sanad, J D Schmelzer, M Sharma, T H Su, K Sultan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, A Vince, H U Wani, V W S Wong, A Workneh, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, H Nde
Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29083408/exome-wide-association-study-of-plasma-lipids-in-300-000-individuals
#13
Dajiang J Liu, Gina M Peloso, Haojie Yu, Adam S Butterworth, Xiao Wang, Anubha Mahajan, Danish Saleheen, Connor Emdin, Dewan Alam, Alexessander Couto Alves, Philippe Amouyel, Emanuele Di Angelantonio, Dominique Arveiler, Themistocles L Assimes, Paul L Auer, Usman Baber, Christie M Ballantyne, Lia E Bang, Marianne Benn, Joshua C Bis, Michael Boehnke, Eric Boerwinkle, Jette Bork-Jensen, Erwin P Bottinger, Ivan Brandslund, Morris Brown, Fabio Busonero, Mark J Caulfield, John C Chambers, Daniel I Chasman, Y Eugene Chen, Yii-Der Ida Chen, Rajiv Chowdhury, Cramer Christensen, Audrey Y Chu, John M Connell, Francesco Cucca, L Adrienne Cupples, Scott M Damrauer, Gail Davies, Ian J Deary, George Dedoussis, Joshua C Denny, Anna Dominiczak, Marie-Pierre Dubé, Tapani Ebeling, Gudny Eiriksdottir, Tõnu Esko, Aliki-Eleni Farmaki, Mary F Feitosa, Marco Ferrario, Jean Ferrieres, Ian Ford, Myriam Fornage, Paul W Franks, Timothy M Frayling, Ruth Frikke-Schmidt, Lars G Fritsche, Philippe Frossard, Valentin Fuster, Santhi K Ganesh, Wei Gao, Melissa E Garcia, Christian Gieger, Franco Giulianini, Mark O Goodarzi, Harald Grallert, Niels Grarup, Leif Groop, Megan L Grove, Vilmundur Gudnason, Torben Hansen, Tamara B Harris, Caroline Hayward, Joel N Hirschhorn, Oddgeir L Holmen, Jennifer Huffman, Yong Huo, Kristian Hveem, Sehrish Jabeen, Anne U Jackson, Johanna Jakobsdottir, Marjo-Riitta Jarvelin, Gorm B Jensen, Marit E Jørgensen, J Wouter Jukema, Johanne M Justesen, Pia R Kamstrup, Stavroula Kanoni, Fredrik Karpe, Frank Kee, Amit V Khera, Derek Klarin, Heikki A Koistinen, Jaspal S Kooner, Charles Kooperberg, Kari Kuulasmaa, Johanna Kuusisto, Markku Laakso, Timo Lakka, Claudia Langenberg, Anne Langsted, Lenore J Launer, Torsten Lauritzen, David C M Liewald, Li An Lin, Allan Linneberg, Ruth J F Loos, Yingchang Lu, Xiangfeng Lu, Reedik Mägi, Anders Malarstig, Ani Manichaikul, Alisa K Manning, Pekka Mäntyselkä, Eirini Marouli, Nicholas G D Masca, Andrea Maschio, James B Meigs, Olle Melander, Andres Metspalu, Andrew P Morris, Alanna C Morrison, Antonella Mulas, Martina Müller-Nurasyid, Patricia B Munroe, Matt J Neville, Jonas B Nielsen, Sune F Nielsen, Børge G Nordestgaard, Jose M Ordovas, Roxana Mehran, Christoper J O'Donnell, Marju Orho-Melander, Cliona M Molony, Pieter Muntendam, Sandosh Padmanabhan, Colin N A Palmer, Dorota Pasko, Aniruddh P Patel, Oluf Pedersen, Markus Perola, Annette Peters, Charlotta Pisinger, Giorgio Pistis, Ozren Polasek, Neil Poulter, Bruce M Psaty, Daniel J Rader, Asif Rasheed, Rainer Rauramaa, Dermot F Reilly, Alex P Reiner, Frida Renström, Stephen S Rich, Paul M Ridker, John D Rioux, Neil R Robertson, Dan M Roden, Jerome I Rotter, Igor Rudan, Veikko Salomaa, Nilesh J Samani, Serena Sanna, Naveed Sattar, Ellen M Schmidt, Robert A Scott, Peter Sever, Raquel S Sevilla, Christian M Shaffer, Xueling Sim, Suthesh Sivapalaratnam, Kerrin S Small, Albert V Smith, Blair H Smith, Sangeetha Somayajula, Lorraine Southam, Timothy D Spector, Elizabeth K Speliotes, John M Starr, Kathleen E Stirrups, Nathan Stitziel, Konstantin Strauch, Heather M Stringham, Praveen Surendran, Hayato Tada, Alan R Tall, Hua Tang, Jean-Claude Tardif, Kent D Taylor, Stella Trompet, Philip S Tsao, Jaakko Tuomilehto, Anne Tybjaerg-Hansen, Natalie R van Zuydam, Anette Varbo, Tibor V Varga, Jarmo Virtamo, Melanie Waldenberger, Nan Wang, Nick J Wareham, Helen R Warren, Peter E Weeke, Joshua Weinstock, Jennifer Wessel, James G Wilson, Peter W F Wilson, Ming Xu, Hanieh Yaghootkar, Robin Young, Eleftheria Zeggini, He Zhang, Neil S Zheng, Weihua Zhang, Yan Zhang, Wei Zhou, Yanhua Zhou, Magdalena Zoledziewska, Joanna M M Howson, John Danesh, Mark I McCarthy, Chad A Cowan, Goncalo Abecasis, Panos Deloukas, Kiran Musunuru, Cristen J Willer, Sekar Kathiresan
We screened variants on an exome-focused genotyping array in >300,000 participants (replication in >280,000 participants) and identified 444 independent variants in 250 loci significantly associated with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), and/or triglycerides (TG). At two loci (JAK2 and A1CF), experimental analysis in mice showed lipid changes consistent with the human data. We also found that: (i) beta-thalassemia trait carriers displayed lower TC and were protected from coronary artery disease (CAD); (ii) excluding the CETP locus, there was not a predictable relationship between plasma HDL-C and risk for age-related macular degeneration; (iii) only some mechanisms of lowering LDL-C appeared to increase risk for type 2 diabetes (T2D); and (iv) TG-lowering alleles involved in hepatic production of TG-rich lipoproteins (TM6SF2 and PNPLA3) tracked with higher liver fat, higher risk for T2D, and lower risk for CAD, whereas TG-lowering alleles involved in peripheral lipolysis (LPL and ANGPTL4) had no effect on liver fat but decreased risks for both T2D and CAD...
October 30, 2017: Nature Genetics
https://www.readbyqxmd.com/read/29045541/from-hepatitis-c-virus-infection-to-b-cell-lymphoma
#14
L Couronné, E Bachy, S Roulland, B Nadel, F Davi, M Armand, D Canioni, J M Michot, C Visco, L Arcaini, C Besson, O Hermine
In addition to liver disorders, hepatitis C virus (HCV) is also associated with extrahepatic immune manifestations and B-cell non-Hodgkin lymphoma (NHL), especially marginal zone lymphoma, de novo or transformed diffuse large B-cell lymphoma and to a lesser extent, follicular lymphoma. Epidemiological data and clinical observations argue for an association between HCV and lymphoproliferative disorders. The causative role of HCV in NHL has been further supported by the response to antiviral therapy. Pathophysiological processes at stake leading from HCV infection to overt lymphoma still need to be further elucidated...
January 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29019615/haemodynamic-profiles-of-children-with-end-stage-heart-failure
#15
Sharon Chen, John C Dykes, Doff B McElhinney, Robert J Gajarski, Andrew Y Shin, Seth A Hollander, Melanie E Everitt, Jack F Price, Ravi R Thiagarajan, Steven J Kindel, Joseph W Rossano, Beth D Kaufman, Lindsay J May, Elizabeth Pruitt, David N Rosenthal, Christopher S Almond
Aims: To evaluate associations between haemodynamic profiles and symptoms, end-organ function and outcome in children listed for heart transplantation. Methods and results: Children <18 years listed for heart transplant between 1993 and 2013 with cardiac catheterization data [pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), and cardiac index (CI)] in the Pediatric Heart Transplant Study database were included. Outcomes were New York Heart Association (NYHA)/Ross classification, renal and hepatic dysfunction, and death or clinical deterioration while on waitlist...
October 7, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28954340/-intervention-effects-of-dan-fang-capsule-in-rats-with-hepatic-fibrosis
#16
X H Hu, J Wu, S Lu
Objective: To investigate the interventional effect of Dan-fang capsule on liver fibrosis in rats. Methods: Sixty one-week aged male healthy SD rats [weight (180±20) g] were randomly divided into normal control group (group A), hepatic fibrosis model group (group B), Fu-Fang-Bie-Jia-Ruan-Gan tablet group (group C), Dan-fang capsule groups at high, middle and low dose group (group D, E, F, respectively). Except for the normal control group, hepatic fibrosis was induced in other groups by intraperitoneal injection of porcine serum...
September 19, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28856540/liver-failure-determines-the-outcome-in-patients-of-acute-on-chronic-liver-failure-aclf-comparison-of-apasl-aclf-research-consortium-aarc-and-clif-sofa-models
#17
A Choudhury, A Jindal, R Maiwall, M K Sharma, B C Sharma, V Pamecha, M Mahtab, S Rahman, Y K Chawla, S Taneja, S S Tan, H Devarbhavi, Z Duan, Chen Yu, Q Ning, Ji Dong Jia, D Amarapurkar, C E Eapen, A Goel, S S Hamid, A S Butt, W Jafri, D J Kim, H Ghazinian, G H Lee, Ajit Sood, L A Lesmana, Z Abbas, G Shiha, D A Payawal, A K Dokmeci, J D Sollano, G Carpio, G K Lau, F Karim, P N Rao, R Moreau, P Jain, P Bhatia, G Kumar, S K Sarin
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models. METHODS: A total of 1402 ACLF patients, enrolled in the APASL-ACLF Research Consortium (AARC) with 90-day follow-up, were analyzed. An ACLF score was developed in a derivation cohort (n = 480) and was validated (n = 922)...
September 2017: Hepatology International
https://www.readbyqxmd.com/read/28839368/intervention-effects-of-atorvastatin-combined-with-panax-notoginseng-saponins-on-rats-with-atherosclerosis-complicated-with-hepatic-injury
#18
Qing-Fang Jiang, Min-Yi Huang, Kang-Yuan Wu, Jie-Ling Weng, Rong-Gui Deng, Xin-Jie Xu, Jian-Pei Xu, Tao Jiang
BACKGROUND: Statins cannot be used for some active liver diseases, which limits its application to some extent. The combined use of statins with other drugs may be one of the ways to solve this dilemma. OBJECTIVE: This research aims to evaluate the effects of atorvastatin combined with Panax notoginseng saponins (PNS) on rats with atherosclerosis (AS) complicated with hepatic injury. MATERIALS AND METHODS: Seventy-two male Wistar rats were randomly categorized into control group (without any intervention, Group A) and AS model groups, which were divided into hepatic injury (Groups B-E) and nonhepatic injury (Groups F-I) groups...
July 2017: Pharmacognosy Magazine
https://www.readbyqxmd.com/read/28827173/heterogeneous-recombination-among-hepatitis-b-virus-genotypes
#19
Nadine Castelhano, Natalia M Araujo, Miguel Arenas
The rapid evolution of Hepatitis B virus (HBV) through both evolutionary forces, mutation and recombination, allows this virus to generate a large variety of adapted variants at both intra and inter-host levels. It can, for instance, generate drug resistance or the diverse viral genotypes that currently exist in the HBV epidemics. Concerning the latter, it is known that recombination played a major role in the emergence and genetic diversification of novel genotypes. In this regard, the quantification of viral recombination in each genotype can provide relevant information to devise expectations about the evolutionary trends of the epidemic...
August 18, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28815408/diphenyl-diselenide-modulates-nucleotidases-reducing-inflammatory-responses-in-the-liver-of-toxoplasma-gondii-infected-mice
#20
Pedro H Doleski, Daniela B R Leal, Vanessa S Machado, Nathieli B Bottari, Alessandra G Manzoni, Emerson A Casali, Cesar E J Moritz, Ana C A Rocha, Giovana Camillo, Fernanda F Vogel, Lenita M Stefani, Ricardo E Mendes, Aleksandro Schafer da Silva
The aim of this study was to verify the effect of diphenyl diselenide (PhSe)2 on hepatic nucleotidases and on the concentration of purines in mice infected by Toxoplasma gondii. The animals were divided into four groups: Group A (uninfected), Group B (uninfected and treated with (PhSe)2), Group C (infected), and Group D (infected and treated with (PhSe)2). The inoculation (groups C and D) was performed with 50 cysts of T. gondii (ME-49 strain). Mice from groups B and D were treated with 5 μmol kg(-1) of (PhSe)2...
August 16, 2017: Purinergic Signalling
keyword
keyword
105123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"